not tend to live as close to their birds as those in Southeast Asia, so, even if bird flu spread to Europe, it would still be more likely to cross the species barrier to humans in Asia than anywhere else. So, while the virus may be hitching a ride on migrating birds, the risks remain essentially unchanged, and they are more easily controlled in Europe than in the poorer countries of Asia.
In contrast, the news that live copies of the virus that caused the 'Spanish flu' pandemic in 1918 are being cultivated in US laboratories, together with the publication of the entire genome of the pathogen has added a new dimension to the discussion. This work delivers a prime example of the so-called 'dual-use' research,
The new strain of bird flu first identified in southern Asia has now reached Europe, raising local fears about a jump to humans as researchers have controversially reconstructed the deadly Spanish flu virus as a means to determine the factors contributing to its virulence. Michael Gross reports.
Under threat: Europe's poultry industry is facing a challenge from the virulent strain of bird flu first identified in southern Asia amidst growing worries that it may transfer to humans. The foundation of this controversial work is an inconspicuous 'letter' in Nature, where Jeffery Taubenberger and his coworkers at the Armed Forces Institute of Pathology at Rockville, Maryland report the sequences of the last three genes of the virus, thus completing its genome. As a prerequisite for its publication, the researchers had to make the sequence publicly available in a database. Using this sequence, the group of Terrence M. Tumpey at the Center for Disease Control and Prevention in Atlanta, Georgia recreated the virus and used it to infect laboratory mice and study its effects in comparison to modern flu viruses. This work was published in Science on October 7th, one day after the sequence paper appeared in Nature.
The editors-in-chief of both journals have underlined their belief that the benefits outweighed any risks. Nevertheless, the reaction in the general media contained more than just an undertone of fear, as the tens of millions who succumbed to this virus in 1918/19 were evoked. Critics cited in the media mainly expressed fears over two aspects, firstly the risk of the recreated virus escaping from the lab (which is only a level 3 biosecurity lab, while the highest security level would be 4), and secondly the risk of somebody rebuilding their own copy of the virus based on the published sequence.
While not denying these risks, proponents of the publications play them down. Building and decorating firms have been sent threatening letters believed to be from animal rights activists warning them not to work for Oxford University which is constructing a major new biomedical facility at its science campus in the heart of the city.
The local Thames Valley police said it knew of 18 anonymous letters that tell contractors that they will be targeted by the militant Animal Liberation Front (AFL) group if they undertake work for the university.
Detectives believe it is likely other people may have been targeted, but chose not to report the letter to the police. A police spokesman said: "It is believed the letters are part of a campaign by animal rights extremists who are trying to prevent work by Oxford University to build new laboratories.
"Although everyone is entitled to an opinion about this very emotive issue, it is just not acceptable to act in a way which intimidates other people and threatens their livelihood." An Oxford University spokesman said: "The university remains firmly committed to the completion of its new biomedical research facility, which has been designed to reflect the latest understanding of best practice in animal welfare.
"It is totally unacceptable that companies engaged in entirely lawful activities are being threatened in this way. We would urge anyone who receives such a letter to contact the police immediately."
Animal rights protests build
Opposition to animal experiments in Britain appears to be extending beyond the labs to other businesses supplying them. Nigel Williams reports.
